{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3889.8","value":"4585.6"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"7792"}],"units":"cycles"}],"description":"Objective 4: To describe hematological outcomes observed in association with primary and secondary prophylactic use of EP2006 in patients at risk for FN; including break-through episodes of FN.","dispersionType":"Standard Deviation","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006 Cycles"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Absolute Neutrophil Count (ANC) Across All Cycles","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"Per mm^3"}